Evidence map›Paper›PMID 15353407›Full record

Trial reportAmerican journal of physiology. Endocrinology and metabolism2004

Effects of glucagon-like peptide-1 on endothelial function in type 2 diabetes patients with stable coronary artery disease.

Thomas Nyström, Mark K Gutniak, Qimin Zhang, Fan Zhang, Jens Juul Holst, Bo Ahrén, Ake Sjöholm

4 registry-linked trialsAbstract readClinical TrialRandomized Controlled Trial
PubMed Publisher
In one paragraph

Trial report in American journal of physiology. Endocrinology and metabolism, 2004. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 4 registered trials, which are not on this map. Cited by 277 papers, 7 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
277citing papers in PubMed, 7 pooled it
7.4field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT01761318 phase4completedstarted 2013, after this paper: background citation

Magnetic Resonance Assessment of Victoza Efficacy in the Regression of Cardiovascular Dysfunction In Type 2 Diabetes Mellitus

Ran2013Enrolled50Registered outcomes48Posted comparisons0ConditionsCardiovascular Disease, Diabetes Mellitus Type 2, Diastolic Dysfunction, Fatty LiverArmsliraglutide, Liraglutide - Placebo
PMID 16776751PMID 18819705PMID 19915017PMID 19349323PMID 19930006PMID 19805654PMID 15171747PMID 15313949PMID 15582729PMID 15591516PMID 15883751PMID 16123478other papers from this trial
Open the trial in the graph
NCT02621489 phase4completedstarted 2015, after this paper: background citation

Effects on Re-endothelialisation With Bydureon Treatment Add on to Insulin Versus Insulin Alone, Both in Combination With Metformin in Type 2 Diabetic Subjects

Ran2015Enrolled38Registered outcomes16Posted comparisons0ConditionsAtherosclerosis, Diabetes, RestenosisArmsBydureon, Humulin kwickpen, Metformin
PMID 20452396PMID 23241323PMID 23343509PMID 25966620PMID 22390929PMID 20630463other papers from this trial
Open the trial in the graph
NCT04133922 early_phase1withdrawnstarted 2019, after this paper: background citation

Effect of GLP-1 on Microvascular Insulin Responses in Type 1 Diabetes

Ran2019Enrolled0Registered outcomes5Posted comparisons0ConditionsInsulin Sensitivity/Resistance, Type 1 DiabetesArmsDextrose 20 % in Water, GLP-1, Insulin
PMID 27295427PMID 27436611PMID 28479155PMID 15983263PMID 10362825PMID 11914261PMID 12360169PMID 26936306PMID 26455399PMID 25998289PMID 25660575PMID 24658303other papers from this trial
Open the trial in the graph
NCT00923962 nacompletednot on this mapstarted 2009, after this paper: background citation

Endothelial and Metabolic Effects of GLP-1 in Coronary Circulation in Patients With Type 2 Diabetes Mellitus

TypeinterventionalSponsorUniversity Hospital, Gentofte, CopenhagenRan2009 to 2012Enrolled35ConditionsType 2 Diabetes MellitusArmsGlucagon like peptide-1, Adenosine
3 · Its place in the literature

Who cites it

277 citing papers in PubMed, 7 syntheses or guidelines pooled it, 667 citations in OpenAlex.

  1. Pooled it
  2. Meta-analysis of the Effect of Semaglutide on Blood Pressure in Obese Populations.American journal of cardiovascular drugs : drugs, devices, and other interventions · 2025 · on this map
    Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Trial
  9. Trial
  10. Trial
  11. Trial
  12. Trial
  13. Trial
  14. Trial
  15. Trial
  16. Trial
  17. Trial
  18. Trial
  19. Trial
  20. Trial

217 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Thomas NyströmDept. of Internal Medicine, Stockholm South Hospital, Karolinska Institute, Stockholm SE-118 83, Sweden. thomas.nystrom@sos.sll.se
Mark K Gutniak
Qimin Zhang
Fan Zhang
Jens Juul Holst
Bo Ahrén
Ake Sjöholm
Karolinska Institutet · SELund University · SE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

GLP-1 stimulates insulin secretion, suppresses glucagon secretion, delays gastric emptying, and inhibits small bowel motility, all actions contributing to the anti-diabetogenic peptide effect. Endothelial dysfunction is strongly associated with insulin resistance and type 2 diabetes mellitus and may cause the angiopathy typifying this debilitating disease. Therefore, interventions affecting both endothelial dysfunction and insulin resistance may prove useful in improving survival in type 2 diabetes patients. We investigated GLP-1's effect on endothelial function and insulin sensitivity (S(I)) in two groups: 1) 12 type 2 diabetes patients with stable coronary artery disease and 2) 10 healthy subjects with normal endothelial function and S(I). Subjects underwent infusion of recombinant GLP-1 or saline in a random crossover study. Endothelial function was measured by postischemic FMD of brachial artery, using ultrasonography. S(I) [in (10(-4) dl.kg(-1).min(-1))/(muU/ml)] was measured by hyperinsulinemic isoglycemic clamp technique. In type 2 diabetic subjects, GLP-1 infusion significantly increased relative changes in brachial artery diameter from baseline FMD(%) (3.1 +/- 0.6 vs. 6.6 +/- 1.0%, P < 0.05), with no significant effects on S(I) (4.5 +/- 0.8 vs. 5.2 +/- 0.9, P = NS). In healthy subjects, GLP-1 infusion affected neither FMD(%) (11.9 +/- 0.9 vs. 10.3 +/- 1.0%, P = NS) nor S(I) (14.8 +/- 1.8 vs. 11.6 +/- 2.0, P = NS). We conclude that GLP-1 improves endothelial dysfunction but not insulin resistance in type 2 diabetic patients with coronary heart disease. This beneficial vascular effect of GLP-1 adds yet another salutary property of the peptide useful in diabetes treatment.

Indexed as

AdultBrachial ArteryCoronary CirculationCoronary DiseaseCoronary VesselsCross-Over StudiesDiabetes Mellitus, Type 2Diabetic AngiopathiesEndothelial CellsEndothelium, VascularGlucagonGlucagon-Like Peptide 1Glucagon-Like Peptide-1 ReceptorHumansInsulinMaleGLP1R protein, humanGlucagonGlucagon-Like Peptide 1Glucagon-Like Peptide-1 ReceptorInsulinNitroglycerinPeptide FragmentsProtein PrecursorsReceptors, Glucagon

Identifiers

PMID15353407
OpenAlexW2129730863

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.